India & Piramal Group
4 shared events · Importance 3 · Last updated Aug 26, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Business
India: Host country of the facility; benefits from increased pharmaceutical manufacturing investment.
Piramal Group: Parent company of PPS; benefits from enhanced CDMO capabilities and potential revenue growth.
Aug 04, 2026 · 12 articles
Business
India: Country where both companies are based; the acquisition strengthens India's biopharma CDMO sector.
Piramal Group: Acquirer; completed acquisition of controlling stake in Yapan Bio, expanding its biologics CDMO capabilities and integrating Yapan Bio as a subsidiary.
Jul 20, 2026 · 11 articles
Business
India: India is the home country of Piramal Group and the location of its CSR initiatives, which positively impacted nearly 1.8 million people across 112 Aspirational Districts. The company's operations and investments contribute to the Indian pharmaceutical sector and community development.
Piramal Group: Piramal Group is the central entity, releasing its sustainability report and announcing key ESG achievements and investments. The report reinforces its commitment to sustainability and quality, which may improve investor perception and support its stock.
Jul 20, 2026 · 12 articles
Business
Piramal Group: Piramal Group previously invested in the Shriram Group and sold its pharmaceutical business.
Dec 19, 2025 · 6 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how India and Piramal Group interact across events, view sentiment trends, and discover connected entities.
Open Dashboard